Fisher Asset Management
LCTX icon

Fisher Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Fisher Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$10.9K – 1013
2023
Q4 		$10.9K Buy
+10,000
New +$11K ﹤0.01% 979

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Fisher Asset Management's LCTX Position: Q1 2024 in Review

Fisher Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q1 2024, closing a stake of 10,000 shares — an estimated $10.9K sold.

Fisher Asset Management first reported a position in LCTX in Q4 2023 and held it in 1 quarter. The position peaked at $10.9K in Q4 2023. 116 funds tracked by Wall St. Rank hold LCTX as of Q1 2024.

  • Fisher Asset Management reported no remaining Lineage Cell Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Fisher Asset Management sold 10,000 Lineage Cell Therapeutics shares in Q1 2024, an estimated $10.9K.
  • Fisher Asset Management first reported a position in Lineage Cell Therapeutics in Q4 2023 and held it in 1 quarter.
  • Fisher Asset Management's Lineage Cell Therapeutics position peaked at $10.9K in Q4 2023.
  • 116 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2024.

Based on Fisher Asset Management's 13F filing for Q1 2024, filed 9 May 2024.